Zenista Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.00 M
as on 17-12-2024
- Revenue 24.61%
(FY 2017)
- Profit 98.41%
(FY 2017)
- Ebitda 140.46%
(FY 2017)
- Net Worth -2.53%
(FY 2017)
- Total Assets -21.54%
(FY 2017)
About Zenista Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Ramesh Verma, Alok Kumar, and Abhay Kumar serve as directors at the Company.
- CIN/LLPIN
U51397BR2013PTC020505
- Company No.
020505
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 2013
- Date of AGM
28 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Zenista Pharmaceuticals Private Limited offer?
Zenista Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Allopathic Cough Syrup.
Who are the key members and board of directors at Zenista Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Verma  | Whole-Time Director | 07-Jun-2013 | Current |
| Alok Kumar | Whole-Time Director | 07-Jun-2013 | Current |
| Abhay Kumar | Whole-Time Director | 07-Jun-2013 | Current |
Financial Performance of Zenista Pharmaceuticals.
Zenista Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 24.61% increase. The company also saw a substantial improvement in profitability, with a 98.41% increase in profit. The company's net worth dipped by a decrease of 2.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zenista Pharmaceuticals?
In 2017, Zenista Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 13 Apr 2016 | ₹1.00 M | Open |
How Many Employees Work at Zenista Pharmaceuticals?
Unlock and access historical data on people associated with Zenista Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zenista Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zenista Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
